Previous 10 | Next 10 |
MOUNTAIN VIEW, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming Lytham Partners ...
The growing demand for healthcare services amid the COVID-19 pandemic has led to substantial capital inflows to the industry. Moreover, disruptive progress in genomics and smart healthcare is expected to be the next big thing. Given the industry’s solid growth prospects, we think funda...
IRIDEX Corporation (IRIX) Q2 2021 Earnings Conference Call August 12, 2021, 05:30 PM ET Company Participants Hunter Cabi - Investor Relations Dave Bruce - CEO Fuad Ahmad - Interim CFO Conference Call Participants Jonathan Block - Stifel Presentation Operator Good day and thank you for standin...
Achieved 116% Year-over-Year Revenue Growth and Record Cyclo G6 Probe Sales Increases Full Year 2021 Guidance MOUNTAIN VIEW, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 3...
MOUNTAIN VIEW, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming H.C. Wainwri...
MOUNTAIN VIEW, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second qua...
IRIX recently blew away analyst estimates for Q1 sales, with multiple tailwinds for continued success in 2021 and beyond. The company’s recent partnership with Japanese giant, Topcon, validates IRIX’s technology and takes the threat of a dilutive capital raise off the ta...
IRIDEX Corporation (IRIX) Q1 2021 Earnings Conference Call May 11, 2021 17:00 ET Company Participants Hunter Cabi - Investor Relations Dave Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Scott Henry - ROTH Capital...
IRIDEX (IRIX): Q1 GAAP EPS of -$0.14 in-line.Revenue of $11.96M (+32.6% Y/Y) beats by $2.06M.Press Release For further details see: IRIDEX EPS in-line, beats on revenue
MOUNTAIN VIEW, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 3, 2021. First Quarter Highlights Closed strategic collaboration with Topcon Corporation netting $19.5 million in new fu...
News, Short Squeeze, Breakout and More Instantly...
MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company...